Time-Dependent Changes in Death Reports and the Sex Ratio in the Safety Surveillance of SARS-CoV-2 Vaccination in Japan, the United States, and European Countries.

adverse event covid-19 vaccines older adult open database safety surveillance

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Mar 2022
Historique:
accepted: 22 03 2022
entrez: 27 4 2022
pubmed: 28 4 2022
medline: 28 4 2022
Statut: epublish

Résumé

The national safety surveillance of vaccines is a fundamental measure to ensure vaccination safety and maintain transparency and public trust. Our previous study revealed an early increase in death reports after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in Japanese surveillance despite our hypothesis that no time-dependent variations in the number of death reports would be seen if the vaccination is not related to serious adverse events. This study is an extensive investigation to determine whether the number of death reports varied consistently over time after vaccination in the older population in Japan, the US, and European countries. We collected the death reports after BNT162b2 mRNA vaccination in individuals aged 65 years or older using the open databases in Japan, the US (Vaccine Adverse Event Reporting System, VAERS), and European countries (EudraVigilance). We observed an early increase of death reports on Day 2 after the vaccination in all three databases. The female-to-male ratio was also assessed and showed a certain degree of time-dependence (

Identifiants

pubmed: 35475057
doi: 10.7759/cureus.23380
pmc: PMC9022046
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e23380

Informations de copyright

Copyright © 2022, Yamashita et al.

Déclaration de conflit d'intérêts

The authors have declared financial relationships, which are detailed in the next section.

Références

Vaccines (Basel). 2020 Jul 03;8(3):
pubmed: 32635349
N Engl J Med. 2021 Dec 2;385(23):2140-2149
pubmed: 34614328
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Drug Saf. 2018 Jul;41(7):665-675
pubmed: 29520645
BMJ. 2021 Dec 13;375:n3074
pubmed: 34903557
Bull World Health Organ. 2022 Jan 1;100(1):2-2A
pubmed: 35017748
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
BMJ. 2021 Dec 20;375:n3105
pubmed: 34930779
Lancet Infect Dis. 2021 Sep;21(9):1193
pubmed: 34391506
Front Med (Lausanne). 2021 Jul 19;8:700014
pubmed: 34350199
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Vaccine. 2022 Jan 24;40(3):477-482
pubmed: 34916104
Infect Dis Rep. 2021 Oct 28;13(4):924-929
pubmed: 34842753
Vaccine. 2015 Aug 26;33(36):4398-405
pubmed: 26209838
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2022 Jan 6;386(1):35-46
pubmed: 34752019
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Erika Yamashita (E)

Research Division, Medical Governance Research Institute, Minato-ku, Tokyo, JPN.

Morihito Takita (M)

Research Division, Medical Governance Research Institute, Minato-ku, Tokyo, JPN.

Masahiro Kami (M)

Research Division, Medical Governance Research Institute, Minato-ku, Tokyo, JPN.

Classifications MeSH